CRISPR THERAPEUTICS AG Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
CRISPR THERAPEUTICS AG (CRSP) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $1.29 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-03
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $1.29B.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $1.06B.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $193.80M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $125.90M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months as first filed |
|---|---|---|
| 2026-06-30 | $1.29B 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $1.06B 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $193.80M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $125.90M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $366.00M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $288.80M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $451.90M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $112.90M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $995.50M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $893.80M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $463.50M 10-K · filed 2025-02-11 | |
| 2023-09-30 | $783.50M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $820.20M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $630.50M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $628.40M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $814.90M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $917.80M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $534.90M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $1.31B 10-K · filed 2023-02-21 | $1.31M 10-K · filed 2022-02-15 |
| 2021-09-30 | $1.03B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $622.60M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $473.70M 10-Q · filed 2021-04-27 | |
| 2020-12-31 | $280.30M 10-K · filed 2022-02-15 | |
| 2020-09-30 | $107.90M 10-Q · filed 2020-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |